Pharmaceutical Technology

FEBRUARY 24, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Amivantamab overview Amivantamab-vmjw (Rybrevant) is a low-fucose human immunoglobulin G1-based bispecific antibody developed using recombinant DNA technology.

Recombinant DNA Technology 100

Recombinant DNA Technology Production Antibody FDA Approval 100

Drug Discovery World

DECEMBER 29, 2022

Recombinant DNA technology and its impact on modern drug discovery . Now is the time for the transformation of clinical trials . Sitting Down With . Catch up on the Sitting Down With podcast episodes released in 2022: . How to accelerate mouse model generation without reducing quality . Narrated Podcasts.

Recombinant DNA Technology 52

Recombinant DNA Technology Genome Genomics DNA 52

pharmaphorum

FEBRUARY 22, 2021

In December interim phase 1/2 trial results showed the vaccine produced a lower immune response in older adults. The vaccine is based around an adjuvanted recombinant protein, which will be tested in a new phase 2 study to assess the response including in older adults.

Vaccination 89

Vaccination Vaccine Recombinant DNA Technology Trials 89

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130